BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 27028190)

  • 1. Initial Use of High-Dose Anticholinergics Combined with Alpha-Blockers for Male Lower Urinary Tract Symptoms with Overactive Bladder: A Prospective, Randomized Preliminary Study.
    Lee KW; Hur KJ; Kim SH; Cho SY; Bae SR; Park BH; Lee YS; Han CH; Kim HW
    Low Urin Tract Symptoms; 2017 Sep; 9(3):129-133. PubMed ID: 27028190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
    Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
    Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A Crossover Comparison Study on Lower Urinary Tract Symptoms with Overactive Bladder Secondary to Benign Prostatic Hyperplasia: Naftopidil versus Tamsulosin with Solifenacin].
    Utsunomiya N; Matsumoto K; Tsunemori H; Muguruma K; Kawakita M; Kamiyama Y; Kanamaru S; Ito N; Tsukazaki H; Shirahase T; Takahashi T
    Hinyokika Kiyo; 2016 Jul; 62(7):341-7. PubMed ID: 27569351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of combination therapy of tamsulosin and solifenacin for mild and moderate benign prostatic hyperplasia with overactive bladder].
    Gao ZW; Xin SY; Zhang JG; Ren XQ; Shang YF; Zhang W; Li HB; Xiao F; Shao CS
    Zhonghua Nan Ke Xue; 2014 Mar; 20(3):239-43. PubMed ID: 24738461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study.
    Lee SH; Byun SS; Lee SJ; Kim KH; Lee JY
    Int Urol Nephrol; 2014 Mar; 46(3):523-9. PubMed ID: 24097273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).
    Van Kerrebroeck P; Haab F; Angulo JC; Vik V; Katona F; Garcia-Hernandez A; Klaver M; Traudtner K; Oelke M
    Eur Urol; 2013 Sep; 64(3):398-407. PubMed ID: 23537687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
    Lee SH; Chung BH; Kim SJ; Kim JH; Kim JC; Lee JY
    Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):320-5. PubMed ID: 21788967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive functions and health-related quality of life in men with benign prostatic hyperplasia and symptoms of overactive bladder when treated with a combination of tamsulosin and solifenacin in a higher dosage.
    Kosilov K; Kuzina I; Kuznetsov V; Gainullina Y; Kosilova L; Prokofyeva A; Loparev S
    Aging Male; 2018 Jun; 21(2):121-129. PubMed ID: 29113548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms.
    Lee HN; Lee KS; Kim JC; Chung BH; Kim CS; Lee JG; Kim DK; Park CH; Park JK; Hong SJ
    Int J Clin Pract; 2015 Apr; 69(4):444-53. PubMed ID: 25363606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tamsulosin hydrochloride 0.2 mg and combination of tamsulosin hydrochloride 0.2 mg plus solifenacin succinate 5 mg after transurethral resection of the prostate: a prospective, randomized controlled trial.
    Shin YS; Zhang LT; You JH; Choi IS; Zhao C; Park JK
    Clin Interv Aging; 2016; 11():1301-1307. PubMed ID: 27698559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction.
    Ichihara K; Masumori N; Fukuta F; Tsukamoto T; Iwasawa A; Tanaka Y
    J Urol; 2015 Mar; 193(3):921-6. PubMed ID: 25254938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of solifenacin with tamsulosin reduces prostate volume and vascularity as opposed to tamsulosin monotherapy in patients with benign prostate enlargement and overactive bladder symptoms: Results from a randomized pilot study.
    Sakalis V; Sfiggas V; Vouros I; Salpiggidis G; Papathanasiou A; Apostolidis A
    Int J Urol; 2018 Aug; 25(8):737-745. PubMed ID: 30008188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twelve-week, prospective, open-label, randomized trial on the effects of an anticholinergic agent or antidiuretic agent as add-on therapy to an alpha-blocker for lower urinary tract symptoms.
    Shin YS; Zhang LT; Zhao C; Kim YG; Park JK
    Clin Interv Aging; 2014; 9():1021-30. PubMed ID: 25031529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of improvement in lower urinary tract symptoms on sexual function in men: tamsulosin monotherapy vs. combination therapy of tamsulosin and solifenacin.
    Ko K; Yang DY; Lee WK; Kim SW; Moon du G; Moon KH; Park NC; Park JK; Son HC; Lee SW; Hyun JS; Park K
    Korean J Urol; 2014 Sep; 55(9):608-14. PubMed ID: 25237463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
    Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
    JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite α-blocker treatment in patients with BPH: the ADDITION study.
    Takeda M; Nishizawa O; Gotoh M; Yoshida M; Takahashi S; Masumori N
    Urology; 2013 Oct; 82(4):887-93. PubMed ID: 23953605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of alfuzosin 10 mg with or without propiverine 10 mg, 20 mg in men with lower urinary tract symptom and an overactive bladder: randomised, single-blind, prospective study.
    Cho HJ; Shin SC; Seo DY; Cho JM; Kang JY; Yoo TK; Yu JH; Sung LH; Moon HS
    Int J Clin Pract; 2014 Apr; 68(4):471-7. PubMed ID: 24471868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.